|
|
|
Insider
Information: |
Cox John |
Relationship: |
|
City: |
Weston |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
5 |
|
Direct
Shares |
44,968 |
|
Indirect Shares
|
4,444 |
|
|
Direct
Value |
$8,806,473 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
49,412 |
|
|
Total
Value |
$8,806,473 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
4
|
Stock
price went up :
|
0
|
4
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
Percentage
Gain/Loss : |
0.0%
|
401.8%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Biogen Idec Inc |
BIIB |
EVP Pharmaceutical Ope... |
2016-04-01 |
39,045 |
|
0 |
Premium* |
|
Repligen Corp |
RGEN |
Director |
2020-03-24 |
923 |
2015-05-21 |
0 |
Premium* |
|
Bioverativ Inc. |
BIVV |
Chief Executive Office... |
2018-03-08 |
0 |
2017-02-28 |
0 |
Premium* |
|
Sigilon Therapeutics, Inc. |
SGTX |
|
2023-08-11 |
0 |
2020-12-08 |
4,444 |
Premium* |
|
Dyne Therapeutics, Inc. |
DYN |
|
2024-03-25 |
5,000 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
BIVV |
Bioverativ Inc. |
Chief Executive Officer |
|
2017-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
211,679 |
226,979 |
0 |
- |
|
BIVV |
Bioverativ Inc. |
Chief Executive Officer |
|
2018-03-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(185,094) |
0 |
0 |
- |
|
BIVV |
Bioverativ Inc. |
Chief Executive Officer |
|
2017-02-28 |
4 |
D |
$43.42 |
$1,748,144 |
D/D |
(37,931) |
189,048 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2011-04-13 |
4 |
AS |
$80.00 |
$2,898,720 |
D/D |
(36,234) |
10,353 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2011-04-13 |
4 |
OE |
$49.31 |
$2,055,646 |
D/D |
36,234 |
46,587 |
0 |
- |
|
RGEN |
Repligen Corp |
Director |
|
2020-03-18 |
4 |
OE |
$12.91 |
$651,603 |
D/D |
26,736 |
29,517 |
0 |
- |
|
RGEN |
Repligen Corp |
Director |
|
2020-03-18 |
4 |
S |
$95.13 |
$2,547,035 |
D/D |
(26,736) |
2,781 |
0 |
% |
|
BIVV |
Bioverativ Inc. |
Chief Executive Officer |
|
2018-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,339 |
215,680 |
0 |
- |
|
BIVV |
Bioverativ Inc. |
Chief Executive Officer |
|
2018-02-11 |
4 |
OE |
$9.53 |
$175,171 |
D/D |
18,381 |
199,013 |
0 |
- |
|
BIVV |
Bioverativ Inc. |
Chief Executive Officer |
|
2018-02-22 |
4 |
D |
$104.30 |
$1,457,384 |
D/D |
(13,973) |
190,888 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2015-03-25 |
4 |
AS |
$449.06 |
$5,393,211 |
D/D |
(12,010) |
25,567 |
0 |
- |
|
BIVV |
Bioverativ Inc. |
Chief Executive Officer |
|
2018-02-14 |
4 |
D |
$103.52 |
$1,119,983 |
D/D |
(10,819) |
204,861 |
0 |
- |
|
RGEN |
Repligen Corp |
Director |
|
2020-03-04 |
4 |
S |
$93.39 |
$933,900 |
D/D |
(10,000) |
2,781 |
0 |
% |
|
RGEN |
Repligen Corp |
Director |
|
2020-03-04 |
4 |
OE |
$12.91 |
$129,100 |
D/D |
10,000 |
12,781 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2016-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,444 |
39,045 |
0 |
- |
|
BIVV |
Bioverativ Inc. |
Chief Executive Officer |
|
2017-03-31 |
4 |
D |
$54.46 |
$458,335 |
D/D |
(8,416) |
180,632 |
0 |
- |
|
BIVV |
Bioverativ Inc. |
Chief Executive Officer |
|
2018-02-11 |
4 |
D |
$103.05 |
$790,600 |
D/D |
(7,672) |
191,341 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2010-10-28 |
4 |
OE |
$33.97 |
$234,393 |
D/D |
6,900 |
25,154 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2010-10-28 |
4 |
AS |
$63.00 |
$434,700 |
D/D |
(6,900) |
18,254 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2011-04-11 |
4 |
AS |
$78.00 |
$538,200 |
D/D |
(6,900) |
10,353 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2011-04-11 |
4 |
OE |
$47.92 |
$330,648 |
D/D |
6,900 |
17,253 |
0 |
- |
|
BIVV |
Bioverativ Inc. |
Chief Executive Officer |
|
2018-02-23 |
4 |
D |
$104.74 |
$606,864 |
D/D |
(5,794) |
185,094 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2015-03-25 |
4 |
OE |
$60.56 |
$333,571 |
D/D |
5,066 |
37,577 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2012-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,692 |
14,280 |
0 |
- |
|
BIIB |
Biogen Idec Inc |
EVP Pharmaceutical Oper & Tech |
|
2013-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,692 |
19,224 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|